INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease

2 years ago

Boca Raton, Florida, Nov. 27, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company…

RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy

2 years ago

Positive clinical and molecular effects observed, with improvements demonstrated in key exploratory efficacy endpoints - percent change in EASI, EASI-50,…

binx health Expands Nationwide Distribution of the binx io Molecular Point-of-Care Platform

2 years ago

BOSTON, Nov. 27, 2023 (GLOBE NEWSWIRE) -- binx health, a healthcare technology and diagnostics company focused on making routine testing…

89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)

2 years ago

—Data at week 48 demonstrated that treatment with pegozafermin led to sustained statistically significant improvements across liver fat and non-invasive…

Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus

2 years ago

Gracell is pioneering use of a CD19/BCMA dual-targeted CAR-T cell therapy in refractory systemic lupus erythematosus, aiming for deeper and…

Recce Pharmaceuticals Granted New Patent in Canada for RECCE® Anti-Infectives

2 years ago

SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new…

Anavex Life Sciences Reports Fiscal 2023 Year End Financial Results and Provides Business Update

2 years ago

Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Anavex…

Cronos Group Inc. enters into agreement for the sale-leaseback of its Stayner, Ontario facility

2 years ago

TORONTO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) today announced that…

Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)

2 years ago

- PDUFA target action date is May 25, 2024 - - FDA does not currently plan to hold Advisory Committee…

PickleJar Announces Conclusion of Definitive Agreements With NewRegen to Accelerate Growth and Capitalization Plan

2 years ago

ATLANTA, GA and HOUSTON, TX, Nov. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- NewRegen (OTC: NREG) and PickleJar Holdings,…